person · Reporting owner

Vessey Rupert

Disclosed activity across 5 companies

Tapewire entity: 15357
SEC CIK: 0001677618

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BIO-TECHNE CorpTECH · Entity 3479	Director	October 30, 2025	November 03, 2025
BRISTOL MYERS SQUIBB COBMY · Entity 1662	EVP & President, Research	May 03, 2023	May 04, 2023
Generate Biomedicines, Inc.GENB · Entity 1553	Director	February 26, 2026	March 02, 2026
Juno Therapeutics, Inc.JUNO · Entity 168572	Director	April 13, 2017	April 19, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIO-TECHNE Corp

Report date October 30, 2025 · Filed November 03, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,987	Reported balance After 2025-10-30 transaction · row 1 1 source row Row 1 · 2025-10-30 · Grant · Acquired 1,640 · Balance 10,987
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.96 · Expires 2035-10-30	Direct	3,777	Reported balance After 2025-10-30 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-10-30 · Grant · Acquired 3,777 · Balance 3,777 F1: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.41 · Expires 2029-10-24	Direct	8,044	Reported balance Holding disclosure · report date 2025-10-30 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance 8,044
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.32 · Expires 2029-06-30	Direct	2,352	Reported balance Holding disclosure · report date 2025-10-30 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance 2,352
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.92 · Expires 2030-10-29	Direct	6,028	Reported balance Holding disclosure · report date 2025-10-30 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance 6,028
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.81 · Expires 2031-10-28	Direct	2,532	Reported balance Holding disclosure · report date 2025-10-30 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance 2,532
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $73.94 · Expires 2032-10-27	Direct	3,460	Reported balance Holding disclosure · report date 2025-10-30 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance 3,460
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.51 · Expires 2033-10-26	Direct	3,937	Reported balance Holding disclosure · report date 2025-10-30 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance 3,937
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.37 · Expires 2034-10-24	Direct	3,511	Reported balance Holding disclosure · report date 2025-10-30 · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · Balance 3,511

Filing footnotes · ownership attribution and instrument terms

F1: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.

BRISTOL MYERS SQUIBB CO

Report date May 03, 2023 · Filed May 04, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.10 par valueSEC Table I · non-derivative	Direct	47,751	Reported balance After 2023-05-03 transaction · row 1 1 source row Row 1 · 2023-05-03 · Sale · Disposed 50,385 · Balance 47,751 F1: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $67.050 to $67.111, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
Common Stock, $0.10 par valueSEC Table I · non-derivative	IndirectBMS Savings and Investment Program	655.73	Reported balance Holding disclosure · report date 2023-05-03 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 655.73 F2: Based on recent 401(k) plan statement.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $67.050 to $67.111, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

F2: Based on recent 401(k) plan statement.

Generate Biomedicines, Inc.

Report date February 26, 2026 · Filed March 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-02-25	Direct	29,561	Reported balance After 2026-02-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-02-26 · Grant · Acquired 29,561 · Balance 29,561 F1: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.

Juno Therapeutics, Inc.

Report date April 13, 2017 · Filed April 19, 2017

This filing explicitly reported no securities owned.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CELGENE CORP /DE/

Report date November 20, 2019 · Filed November 22, 2019

Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2019-11-20 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2019-11-20 · Grant · Acquired 8,634 · Balance 22,812 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 2 · 2019-11-20 · Grant · Acquired 13,906 · Balance 36,718 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 3 · 2019-11-20 · Grant · Acquired 24,209 · Balance 60,927 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 4 · 2019-11-20 · Disposition to issuer · Disposed 60,927 · Balance 0 F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
Common StockSEC Table I · non-derivative	Indirect401(k) Plan	Reported balance After 2019-11-20 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2019-11-20 · Disposition to issuer · Disposed 613 · Balance 0 F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $118.57 · Expires 2025-02-02	Direct	Reported balance After 2019-11-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-11-20 · Disposition to issuer · Disposed 19,142 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $109.90 · Expires 2025-05-04	Direct	Reported balance After 2019-11-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-11-20 · Disposition to issuer · Disposed 3,125 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $132.56 · Expires 2025-07-27	Direct	Reported balance After 2019-11-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-11-20 · Disposition to issuer · Disposed 3,125 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $114.08 · Expires 2025-11-09	Direct	Reported balance After 2019-11-20 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-11-20 · Disposition to issuer · Disposed 3,125 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.80 · Expires 2026-02-01	Direct	Reported balance After 2019-11-20 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2019-11-20 · Disposition to issuer · Disposed 2,344 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $104.97 · Expires 2026-05-02	Direct	Reported balance After 2019-11-20 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2019-11-20 · Disposition to issuer · Disposed 9,680 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $114.69 · Expires 2026-08-01	Direct	Reported balance After 2019-11-20 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2019-11-20 · Disposition to issuer · Disposed 12,906 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $102.18 · Expires 2026-10-31	Direct	Reported balance After 2019-11-20 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2019-11-20 · Disposition to issuer · Disposed 31,210 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $113.18 · Expires 2027-01-30	Direct	Reported balance After 2019-11-20 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2019-11-20 · Disposition to issuer · Disposed 12,906 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $124.06 · Expires 2027-05-01	Direct	Reported balance After 2019-11-20 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2019-11-20 · Disposition to issuer · Disposed 11,384 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $135.41 · Expires 2027-07-31	Direct	Reported balance After 2019-11-20 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2019-11-20 · Disposition to issuer · Disposed 11,384 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.97 · Expires 2027-10-30	Direct	Reported balance After 2019-11-20 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2019-11-20 · Disposition to issuer · Disposed 26,308 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.26 · Expires 2028-01-29	Direct	Reported balance After 2019-11-20 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2019-11-20 · Disposition to issuer · Disposed 11,384 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $83.13 · Expires 2028-05-08	Direct	Reported balance After 2019-11-20 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2019-11-20 · Disposition to issuer · Disposed 18,257 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.91 · Expires 2028-07-30	Direct	Reported balance After 2019-11-20 transaction · row 20 Instrument identity requires review; Table II rows are not merged. 1 source row Row 20 · 2019-11-20 · Disposition to issuer · Disposed 18,257 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.43 · Expires 2028-10-29	Direct	Reported balance After 2019-11-20 transaction · row 21 Instrument identity requires review; Table II rows are not merged. 1 source row Row 21 · 2019-11-20 · Disposition to issuer · Disposed 18,257 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 22 Instrument identity requires review; Table II rows are not merged. 1 source row Row 22 · 2019-11-20 · Disposition to issuer · Disposed 5,756 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 23 Instrument identity requires review; Table II rows are not merged. 1 source row Row 23 · 2019-11-20 · Disposition to issuer · Disposed 3,120 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 24 Instrument identity requires review; Table II rows are not merged. 1 source row Row 24 · 2019-11-20 · Disposition to issuer · Disposed 9,271 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 25 Instrument identity requires review; Table II rows are not merged. 1 source row Row 25 · 2019-11-20 · Disposition to issuer · Disposed 5,794 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 26 Instrument identity requires review; Table II rows are not merged. 1 source row Row 26 · 2019-11-20 · Disposition to issuer · Disposed 37,660 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.

F3: This option was fully exercisable.

F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.

F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 10, 2020 Filed Mar 12, 2020 22:18 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantMarket Share Units · Derivative	29,694	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000127 · wf-form4_158405150564304.xml · derivative · entry 1 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,694 Underlying: Common Stock, $0.10 par value · 29,694 shares Expires 2024-03-10 F1 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F2 · derivative.exercise_date: Twenty-five percent of these market share units will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document
March 02, 2020 Filed Mar 4, 2020 23:19 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionOption (right to buy) · Derivative	8,489	$0.00 Strike: $38.41	$0.00	Disclosure SEC source: 0000014272-20-000092 · wf-form4_158336396499135.xml · derivative · entry 12 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,468 Underlying: Common Stock, $0.10 par value · 8,489 shares Expires 2028-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the shares are currently exercisable. Read SEC document
March 02, 2020 Filed Mar 4, 2020 23:19 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionOption (right to buy) · Derivative	8,489	$0.00 Strike: $47.81	$0.00	Disclosure SEC source: 0000014272-20-000092 · wf-form4_158336396499135.xml · derivative · entry 11 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,469 Underlying: Common Stock, $0.10 par value · 8,489 shares Expires 2028-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the shares are currently exercisable. Read SEC document
March 02, 2020 Filed Mar 4, 2020 23:19 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionOption (right to buy) · Derivative	8,489	$0.00 Strike: $44.70	$0.00	Disclosure SEC source: 0000014272-20-000092 · wf-form4_158336396499135.xml · derivative · entry 10 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,469 Underlying: Common Stock, $0.10 par value · 8,489 shares Expires 2028-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the shares are currently exercisable. Read SEC document
March 02, 2020 Filed Mar 4, 2020 23:19 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionOption (right to buy) · Derivative	24,466	$0.00 Strike: $54.29	$0.00	Disclosure SEC source: 0000014272-20-000092 · wf-form4_158336396499135.xml · derivative · entry 9 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,466 Underlying: Common Stock, $0.10 par value · 24,466 shares Expires 2027-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the shares are currently exercisable. Read SEC document
March 02, 2020 Filed Mar 4, 2020 23:19 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionOption (right to buy) · Derivative	43,535	$0.00 Strike: $54.94	$0.00	Disclosure SEC source: 0000014272-20-000092 · wf-form4_158336396499135.xml · derivative · entry 8 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,515 Underlying: Common Stock, $0.10 par value · 43,535 shares Expires 2026-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the shares are currently exercisable. Read SEC document
March 02, 2020 Filed Mar 4, 2020 23:19 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	SaleCommon Stock, $0.10 par value	84,308	$60.59	$5,108,221.72	Disclosure SEC source: 0000014272-20-000092 · wf-form4_158336396499135.xml · nonDerivative · entry 6 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,343 F1 · shares: 84,308 of the shares sold were to cover the exercise price and taxes in accordance with broker's procedures for sell-to-cover transactions. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from 60.33 to 60.71, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F1 · price: 84,308 of the shares sold were to cover the exercise price and taxes in accordance with broker's procedures for sell-to-cover transactions. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from 60.33 to 60.71, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document
March 02, 2020 Filed Mar 4, 2020 23:19 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	8,489	$38.41	$326,062.49	Disclosure SEC source: 0000014272-20-000092 · wf-form4_158336396499135.xml · nonDerivative · entry 5 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,651 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 02, 2020 Filed Mar 4, 2020 23:19 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	8,489	$47.81	$405,859.09	Disclosure SEC source: 0000014272-20-000092 · wf-form4_158336396499135.xml · nonDerivative · entry 4 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 02, 2020 Filed Mar 4, 2020 23:19 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	8,489	$44.70	$379,458.30	Disclosure SEC source: 0000014272-20-000092 · wf-form4_158336396499135.xml · nonDerivative · entry 3 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 02, 2020 Filed Mar 4, 2020 23:19 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	24,466	$54.29	$1,328,259.14	Disclosure SEC source: 0000014272-20-000092 · wf-form4_158336396499135.xml · nonDerivative · entry 2 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 02, 2020 Filed Mar 4, 2020 23:19 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	43,535	$54.94	$2,391,812.90	Disclosure SEC source: 0000014272-20-000092 · wf-form4_158336396499135.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 01, 2020 Filed Mar 4, 2020 01:05 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionRestricted Stock Units · Derivative	23,349	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000090 · wf-form4_158328389331194.xml · derivative · entry 4 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,699 Underlying: Common Stock, $0.10 par value · 23,349 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · shares: The restricted stock unit vests in three equal installments beginning on March 1, 2020. F1 · derivative.exercise_date: The restricted stock unit vests in three equal installments beginning on March 1, 2020. F1 · derivative.expiration_date: The restricted stock unit vests in three equal installments beginning on March 1, 2020. Read SEC document
March 01, 2020 Filed Mar 4, 2020 01:05 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Tax withholdingCommon Stock, $0.10 par value	8,923	$59.06	$526,992.38	Disclosure SEC source: 0000014272-20-000090 · wf-form4_158328389331194.xml · nonDerivative · entry 2 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,183 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document
March 01, 2020 Filed Mar 4, 2020 01:05 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	23,349	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000090 · wf-form4_158328389331194.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock unit vests in three equal installments beginning on March 1, 2020. Read SEC document
February 04, 2020 Filed Feb 7, 2020 01:49 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionRestricted Stock Units · Derivative	3,592	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000079 · wf-form4_158104013763753.xml · derivative · entry 4 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,185 Underlying: Common Stock, $0.10 par value · 3,592 shares Expires 2022-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · shares: The restricted stock unit vests in three equal installments beginning on February 4, 2020. F1 · derivative.exercise_date: The restricted stock unit vests in three equal installments beginning on February 4, 2020. F1 · derivative.expiration_date: The restricted stock unit vests in three equal installments beginning on February 4, 2020. Read SEC document
February 04, 2020 Filed Feb 7, 2020 01:49 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Tax withholdingCommon Stock, $0.10 par value	1,163	$64.29	$74,769.27	Disclosure SEC source: 0000014272-20-000079 · wf-form4_158104013763753.xml · nonDerivative · entry 2 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,757 F2 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document
February 04, 2020 Filed Feb 7, 2020 01:49 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	3,592	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000079 · wf-form4_158104013763753.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock unit vests in three equal installments beginning on February 4, 2020. Read SEC document
December 31, 2019 Filed Jan 4, 2020 00:00 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionRestricted Stock Units · Derivative	16,060	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000029 · wf-form4_157809602702986.xml · derivative · entry 4 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 16,060 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F2 · shares: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. F2 · derivative.exercise_date: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. F2 · derivative.expiration_date: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document
December 31, 2019 Filed Jan 4, 2020 00:00 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Tax withholdingCommon Stock, $0.10 par value	7,910	$64.19	$507,742.90	Disclosure SEC source: 0000014272-20-000029 · wf-form4_157809602702986.xml · nonDerivative · entry 2 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,868 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document
December 31, 2019 Filed Jan 4, 2020 00:00 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	16,060	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000029 · wf-form4_157809602702986.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,778 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: In connection with the merger, all outstanding Celgene Corporation (Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. F2 · shares: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document
December 31, 2019 Filed Jan 15, 2020 22:04 UTC Amendment	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Tax withholdingCommon Stock, $0.10 par value	7,910	$64.19	$507,742.90	Disclosure SEC source: 0000014272-20-000040 · wf-form4a_157912585811970.xml · nonDerivative · entry 2 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,328 F4 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document
December 31, 2019 Filed Jan 15, 2020 22:04 UTC Amendment	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	16,060	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000040 · wf-form4a_157912585811970.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: In connection with the merger, all outstanding Celgene Corporation (Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. F2 · shares: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. F3 · balance_after: Due to an administrative error, this Form 4 is being amended to report in Column 5 the correct number of securities beneficially owned following the reported transaction. Read SEC document
December 02, 2019 Filed Dec 4, 2019 21:59 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	35,168	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000241 · wf-form4_157549675679272.xml · derivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,168 Underlying: Common Stock, $0.10 par value · 35,168 shares Expires 2023-12-02 F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on December 2, 2020. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on December 2, 2020. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerRestricted Stock Unit · Derivative	37,660	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · derivative · entry 26 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,660 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F6 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F6 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerRestricted Stock Unit · Derivative	5,794	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · derivative · entry 25 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,794 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F6 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F6 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerRestricted Stock Unit · Derivative	9,271	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · derivative · entry 24 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,271 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F6 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F6 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerRestricted Stock Unit · Derivative	3,120	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · derivative · entry 23 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,120 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F6 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F6 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerRestricted Stock Unit · Derivative	5,756	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · derivative · entry 22 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,756 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F6 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F6 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	18,257	$0.00 Strike: $71.43	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · derivative · entry 21 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,257 shares Expires 2028-10-29 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	18,257	$0.00 Strike: $88.91	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · derivative · entry 20 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,257 shares Expires 2028-07-30 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	18,257	$0.00 Strike: $83.13	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · derivative · entry 19 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,257 shares Expires 2028-05-08 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	11,384	$0.00 Strike: $103.26	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · derivative · entry 18 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,384 shares Expires 2028-01-29 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	26,308	$0.00 Strike: $100.97	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · derivative · entry 17 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,308 shares Expires 2027-10-30 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	11,384	$0.00 Strike: $135.41	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · derivative · entry 16 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,384 shares Expires 2027-07-31 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	11,384	$0.00 Strike: $124.06	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · derivative · entry 15 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,384 shares Expires 2027-05-01 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	12,906	$0.00 Strike: $113.18	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · derivative · entry 14 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,906 shares Expires 2027-01-30 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	31,210	$0.00 Strike: $102.18	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · derivative · entry 13 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,210 shares Expires 2026-10-31 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	12,906	$0.00 Strike: $114.69	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · derivative · entry 12 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,906 shares Expires 2026-08-01 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	9,680	$0.00 Strike: $104.97	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · derivative · entry 11 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,680 shares Expires 2026-05-02 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	2,344	$0.00 Strike: $100.80	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · derivative · entry 10 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,344 shares Expires 2026-02-01 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	3,125	$0.00 Strike: $114.08	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · derivative · entry 9 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,125 shares Expires 2025-11-09 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	3,125	$0.00 Strike: $132.56	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · derivative · entry 8 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,125 shares Expires 2025-07-27 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	3,125	$0.00 Strike: $109.90	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · derivative · entry 7 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,125 shares Expires 2025-05-04 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	19,142	$0.00 Strike: $118.57	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · derivative · entry 6 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,142 shares Expires 2025-02-02 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerCommon Stock	613	$0.00	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · nonDerivative · entry 5 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Indirect · 401(k) Plan Disclosed balance after: 0 F2 · price: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerCommon Stock	60,927	$0.00	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · nonDerivative · entry 4 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantCommon Stock	24,209	$0.00	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · nonDerivative · entry 3 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,927 F1 · price: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantCommon Stock	13,906	$0.00	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · nonDerivative · entry 2 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,718 F1 · price: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantCommon Stock	8,634	$0.00	$0.00	Disclosure SEC source: 0001415889-19-001382 · form4-11222019_071135.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · PRES., RESEARCH AND EARLY DEV. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,812 F1 · price: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.